Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
- ATI-1701 could be a first-in-class vaccine with no current competition in major markets
- Strong government interest as tularemia is a top biodefense priority
- Collaboration with prestigious institutions like the United States Air Force Academy
- ATI-1701 is still in early development stages, not yet in clinical trials
- No immediate revenue potential as the vaccine is not yet approved
A review of recent findings suggests that Appili鈥檚 biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks
HALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the 鈥淐ompany鈥� or 鈥淎ppili鈥�), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures,听today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial infection. Dr. Carl Gelhaus, Ph.D., Director of NonClinical Research at Appili, together with researchers from the United States Air Force Academy (鈥淯SAFA鈥�), and other U.S. based researchers published the manuscript, 鈥�The Immune Response to Francisella tularensis鈥�.
鈥淎ppili is developing ATI-1701, a biodefense vaccine, to protect warfighters from tularemia,鈥� said Dr. Carl Gelhaus, Director of Non Clinical Research at Appili Therapeutics. 鈥淭ogether with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic. The insights shared in this article will directly inform our ongoing development and help refine immune response targets for ATI-1701.鈥�
The review consolidates recent findings on the immune system response to F. tularensis infections and suggests various means by which infections can be controlled. By examining diverse F. tularensis strains and animal models, the authors identify key correlates of protection and outline promising pathways for effective tularemia vaccine development.
ATI-1701 is the Company鈥檚 potential first-in-class vaccine candidate for the prevention of infection with听F. tularensis. Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for F. tularensis are a top biodefense priority for governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets, strengthening听ATI-1701鈥檚 position as a potentially valuable vaccine urgently needed on the market.
About ATI-1701听
ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be aerosolized and is over 1,000 times more infectious than anthrax. Since it is a highly infectious pathogen capable of causing severe illness, medical counter measures for F. tularensis are a top biodefense priority for the United States and governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.
About Appili Therapeutics听
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili鈥檚 goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit听.
Forward looking statements听
This news release contains 鈥渇orward-looking statements鈥�, including with respect to any potential outbreak of tularemia in the Ukraine, the funding commitment from USAFA, further anticipated milestones and the timing thereof and the Company鈥檚 development plans with respect to ATI-1701. Wherever possible, words such as 鈥渕ay,鈥� 鈥渨ould,鈥� 鈥渃ould,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥減lan,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渆stimate,鈥� 鈥減otential for鈥� and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company鈥檚 management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the risk that ATI-1701 may never become an approved vaccine for the prevention or treatment of tularemia, and the other risks listed in the annual information form of the Company dated June 25, 2024, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
Media Contact:听
Jenna McNeil, Communications Manager听
Appili Therapeutics
E:
Investor Relations Contact:听
Don Cilla, President and CEO听
Appili Therapeutics听
E:
FAQ
What is Appili Therapeutics (APLIF) developing for tularemia prevention?
Are there any approved vaccines for tularemia in the United States?
Why is Appili's tularemia vaccine ATI-1701 important for government agencies?
What was the focus of Appili Therapeutics' recent publication in Frontiers in Bacteriology?
